Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...

Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye ...

Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in ...

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing ...

Cancer patients who received the mRNA-based jab after starting immunotherapy lived significantly longer than those who did ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune ...

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event – Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The ...

October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to report its third quarter 2025 ...

It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal government.

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and ...

To tailor cancer therapies to individual patients, Moderna, BioNTech and other companies are rethinking how they optimize ...